Envista Holdings Co. (NYSE:NVST) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Envista Holdings Co. (NYSE:NVST) have received an average recommendation of “Hold” from the fifteen analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $20.21.

A number of equities analysts have recently commented on the company. Evercore ISI boosted their price target on Envista from $18.00 to $23.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Stifel Nicolaus boosted their target price on Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Piper Sandler raised their price target on shares of Envista from $16.00 to $17.00 and gave the company a “neutral” rating in a research note on Thursday, October 31st. Wells Fargo & Company started coverage on shares of Envista in a research report on Tuesday, October 8th. They set an “equal weight” rating and a $20.00 price objective for the company. Finally, Mizuho assumed coverage on shares of Envista in a research report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 target price on the stock.

Envista Price Performance

Shares of NYSE NVST opened at $19.03 on Monday. The stock has a market capitalization of $3.28 billion, a PE ratio of -2.45, a P/E/G ratio of 2.71 and a beta of 1.33. Envista has a fifty-two week low of $15.15 and a fifty-two week high of $25.64. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. The business has a fifty day moving average price of $20.25 and a two-hundred day moving average price of $18.52.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.03. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The business had revenue of $601.00 million for the quarter, compared to analyst estimates of $590.34 million. During the same quarter last year, the business posted $0.43 EPS. The firm’s revenue for the quarter was down 4.8% on a year-over-year basis. As a group, equities analysts predict that Envista will post 0.72 earnings per share for the current fiscal year.

Institutional Trading of Envista

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Envista in the 3rd quarter worth about $31,000. GAMMA Investing LLC grew its stake in Envista by 69.8% during the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after purchasing an additional 726 shares during the period. Huntington National Bank increased its holdings in Envista by 97.8% in the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after purchasing an additional 949 shares in the last quarter. Blue Trust Inc. lifted its stake in Envista by 69.7% in the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after buying an additional 804 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Envista by 50.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after buying an additional 728 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.